Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Down 25.0% in March

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 9,600 shares, a decrease of 25.0% from the February 28th total of 12,800 shares. Based on an average daily volume of 44,100 shares, the short-interest ratio is presently 0.2 days. Currently, 1.5% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Titan Pharmaceuticals in a research report on Tuesday, March 25th. They set a “sell” rating on the stock.

Titan Pharmaceuticals Trading Down 4.9 %

NASDAQ TTNP opened at $3.68 on Monday. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80. The stock has a market capitalization of $3.36 million, a price-to-earnings ratio of -0.71 and a beta of 1.19. The business’s 50 day moving average is $3.67 and its two-hundred day moving average is $3.98.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) EPS for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.